Risk factors and management of corticosteroid-induced hyperglycaemia in paediatric acute lymphoblastic leukaemia.
Kyriacos GregoriouIan CraigieBrenda GibsonAvril MasonMohamad Guftar ShaikhPublished in: Pediatric blood & cancer (2019)
Corticosteroids are incorporated into protocols for the treatment of acute lymphoblastic leukaemia, and hyperglycaemia is a recognised side effect. Corticosteroids exert their hyperglycaemic effect with a multifactorial mechanism. Complications of hyperglycaemia include an increased risk of infection - bacterial, viral and fungal. Approximately half of the children who develop corticosteroid-associated hyperglycaemia are predicted to require insulin treatment, with age and obesity having found to be predictive factors. Fasting and random glucose values can be used to define hyperglycaemia. This review focuses on the published evidence for significant predictive factors for the development of corticosteroid-induced hyperglycaemia and provides guidance on management.
Keyphrases
- risk factors
- drug induced
- liver failure
- type diabetes
- insulin resistance
- diabetic rats
- high glucose
- intensive care unit
- metabolic syndrome
- respiratory failure
- blood glucose
- sars cov
- combination therapy
- blood pressure
- adipose tissue
- randomized controlled trial
- glycemic control
- oxidative stress
- physical activity
- aortic dissection
- replacement therapy
- extracorporeal membrane oxygenation
- hepatitis b virus